Joel B. Nelson, Karim Fizazi, Kurt Miller, Celestia Higano, Judd W. Moul, Hideyuki Akaza, Thomas Morris, Stuart McIntosh, Kristine Pemberton and Martin Gleave Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone Cancer 118
Version of Record online: 11 JUL 2012 | DOI: 10.1002/cncr.27674
This large, randomized, placebo-controlled phase 3 trial evaluated the endothelin A receptor antagonist zibotentan in patients with castration-resistant prostate cancer metastatic to bone. Treatment with zibotentan 10 mg/day did not lead to a statistically significant improvement in overall survival in this patient population.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field